Search

Your search keyword '"Pinzon-Ortiz, Maria"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Pinzon-Ortiz, Maria" Remove constraint Author: "Pinzon-Ortiz, Maria"
38 results on '"Pinzon-Ortiz, Maria"'

Search Results

3. Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade

4. Supplementary Table 1, Figure Legends 1-6 from A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

5. Supplementary Data from Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

6. Supplementary Figures 1-6 from A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

7. CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

8. Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

9. 248 Immunotherapy persister cells uncovered by dynamic single-cell RNA-sequencing

10. Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

13. The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

15. Synergistic Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

18. Abstract 2522: Molecular and cellular mechanisms underlying the therapeutic efficacy of the combination of JAK inhibitor, ruxolitinib, PIM inhibitor, LGH447, and CDK4/6 inhibitor, LEE011, in a preclinical model of myeloproliferative neoplasia

19. Abstract 2692: High allele frequency of KRAS functional mutations predicts resistance to MEK inhibitors: Evidence from cell lines and human tumor xenograft models

21. The identification and characterization of a STAT5 gene signature in hematologic malignancies

26. The Combination Of JAK Inhibitor, Ruxolitinib, and PIM Inhibitor, LGH447, In Preclinical Models Of Myeloproliferative Neoplasia

28. RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth

31. A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

32. Nmur1−/− mice are not protected from cutaneous inflammation

33. 1 Lack of Nmur1 Does Not Protect Mice From Inflammatory Challenge

34. P4-364 Rapid in-vivo assessment of therapeutic window of two γ-secretase inhibitors in transgenic CRND8 mice

35. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016

36. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

37. Nmur1−/− mice are not protected from cutaneous inflammation

38. The major surface protein of malaria sporozoites is GPI-anchored to the plasma membrane.

Catalog

Books, media, physical & digital resources